Back to Search
Start Over
Cancer Clinical Trials in Africa-An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials.
- Source :
-
JCO global oncology [JCO Glob Oncol] 2021 Aug; Vol. 7, pp. 1358-1363. - Publication Year :
- 2021
-
Abstract
- Cancer is now a formidable health care burden in sub-Saharan Africa (SSA) due to lifestyle westernization and longer life expectancy. The exponential increase in cancer incidence coupled with high mortality rate is not comparable with that seen in westernized countries. To address global cancer disparity, globalization of cancer clinical trials to involve sub-Saharan Africa can serve as a platform where innovative targeted therapies can be made available to patients in the environ. In the 2019 African Organization for Research and Training in Cancer (AORTIC) conference held at Maputo, Mozambique, a group of clinical trialists spanning across multiple continents highlighted the opportunities in Africa for the conduct of cancer clinical trials. The secondary purpose of the meeting was to address the belief that Africa was incapable of conducting interventional cancer trials but showed the in-continent strengths, such as available capacities, trained local clinical trialists with clinical trial experiences, clinical trial consortia, local capabilities, mapping out logistics, ethical consideration, political will, real-time benefits of clinical trials to clinical practice, and future directions for trials.<br />Competing Interests: Colin PillaiEmployment: Roche, CP+ Associates GmbHLeadership: Clinical Research Management LTD (ACE Research), Nairobi, KenyaStock and Other Ownership Interests: Novartis, Alcon, RocheConsulting or Advisory Role: Johnson & Johnson/Janssen Ifeoma OkoyeStock and Other Ownership Interests: Safety Molecular Pathology Laboratory J. Joshua SmithConsulting or Advisory Role: Guardant Health Diane Reidy-LagunesHonoraria: NovartisConsulting or Advisory Role: Lexicon, Advanced Accelerator ApplicationsResearch Funding: Novartis, Ipsen, Merck Grace MacaulayEmployment: MedImmune, Cepheid/DanaherStock and Other Ownership Interests: MedImmuneNo other potential conflicts of interest were reported.
- Subjects :
- Africa
Congresses as Topic
Humans
Clinical Trials as Topic
Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2687-8941
- Volume :
- 7
- Database :
- MEDLINE
- Journal :
- JCO global oncology
- Publication Type :
- Academic Journal
- Accession number :
- 34506222
- Full Text :
- https://doi.org/10.1200/GO.21.00096